Malignant Neoplasm of the Renal Pelvis and Ureter B044
Current RMA Instruments
| Reasonable Hypothesis SOP | 92 of 2019 |
| Balance of Probabilities SOP | 93 of 2019 |
Changes from previous Instruments
ICD Coding
ICD-10-AM Codes: C65, C66
Brief description
This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder).
Confirming the diagnosis
The diagnosis requires confirmation by histology.
The relevant medical specialist is a urologist.
Additional diagnoses covered by SOP
- Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
Related conditions that may be covered by SOP (further information required)
- Cancer of the renal pelvis, renal calyx or ureter
- Renal pelvic and ureteric cancer
Conditions not covered by SOP
- Hodgkin’s lymphoma of the renal calyx, pelvis or ureter*
- Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)
- Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*
- Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)
- Soft-tissue sarcoma of the renal calyx, pelvis or ureter*
* another SOP applies
Clinical onset
The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.
Clinical worsening
The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/sops-grouped-icd-body-system/m/malignant-neoplasm-renal-pelvis-and-ureter-b044-c65c66
Rulebase for malignant neoplasm of the renal pelvis and ureter
<h5>Current RMA Instruments</h5><table border="1" cellpadding="1" cellspacing="1"><tbody><tr><td><a href="http://www.rma.gov.au/assets/SOP/2019/c927871f23/092.pdf" target="_blank">Reasonable Hypothesis SOP</a></td><td><p><span>92 of 2019 </span></p></td></tr><tr><td><a href="http://www.rma.gov.au/assets/SOP/2019/d0dc4faf39/093.pdf" target="_blank">Balance of Probabilities SOP</a></td><td><span>93 of 2019 </span></td></tr></tbody></table><h5>Changes from previous Instruments</h5><p><drupal-media data-entity-type="media" data-entity-uuid="0c4d346f-691c-49bc-ba54-128fde46d9ce" data-view-mode="wysiwyg"></drupal-media></p><h5>ICD Coding</h5><p>ICD-10-AM Codes: C65, C66</p><h5><strong>Brief description</strong></h5><p>This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder). </p><h5><strong>Confirming the diagnosis</strong></h5><p>The diagnosis requires confirmation by histology.</p><p>The relevant medical specialist is a urologist.</p><h5><strong>Additional diagnoses covered by SOP</strong></h5><ul><li>Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter</li><li>Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter</li><li>Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter</li><li>Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter</li><li>Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter</li><li>Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter</li></ul><h5><strong>Related conditions that may be covered by SOP (further information required)</strong></h5><ul><li>Cancer of the renal pelvis, renal calyx or ureter</li><li>Renal pelvic and ureteric cancer</li></ul><h5><strong>Conditions not covered by SOP </strong></h5><ul><li>Hodgkin’s lymphoma of the renal calyx, pelvis or ureter* </li><li>Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)</li><li>Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*</li><li>Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)</li><li>Soft-tissue sarcoma of the renal calyx, pelvis or ureter*</li></ul><p>* another SOP applies</p><h5><strong>Clinical onset</strong></h5><p>The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.</p><h5>Clinical worsening</h5><p>The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.</p><p> </p><p> </p>
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/rulebase-malignant-neoplasm-renal-pelvis-and-ureter
Cigar smoking
Current RMA Instruments
| Reasonable Hypothesis SOP | 92 of 2019 |
| Balance of Probabilities SOP | 93 of 2019 |
Changes from previous Instruments
ICD Coding
ICD-10-AM Codes: C65, C66
Brief description
This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder).
Confirming the diagnosis
The diagnosis requires confirmation by histology.
The relevant medical specialist is a urologist.
Additional diagnoses covered by SOP
- Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
Related conditions that may be covered by SOP (further information required)
- Cancer of the renal pelvis, renal calyx or ureter
- Renal pelvic and ureteric cancer
Conditions not covered by SOP
- Hodgkin’s lymphoma of the renal calyx, pelvis or ureter*
- Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)
- Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*
- Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)
- Soft-tissue sarcoma of the renal calyx, pelvis or ureter*
* another SOP applies
Clinical onset
The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.
Clinical worsening
The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-renal-pelvis-and-ureter-b044-c65c66/rulebase-malignant-neoplasm-renal-pelvis-and-ureter/cigar-smoking
Cigarette smoking
Current RMA Instruments
| Reasonable Hypothesis SOP | 92 of 2019 |
| Balance of Probabilities SOP | 93 of 2019 |
Changes from previous Instruments
ICD Coding
ICD-10-AM Codes: C65, C66
Brief description
This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder).
Confirming the diagnosis
The diagnosis requires confirmation by histology.
The relevant medical specialist is a urologist.
Additional diagnoses covered by SOP
- Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
Related conditions that may be covered by SOP (further information required)
- Cancer of the renal pelvis, renal calyx or ureter
- Renal pelvic and ureteric cancer
Conditions not covered by SOP
- Hodgkin’s lymphoma of the renal calyx, pelvis or ureter*
- Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)
- Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*
- Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)
- Soft-tissue sarcoma of the renal calyx, pelvis or ureter*
* another SOP applies
Clinical onset
The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.
Clinical worsening
The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-renal-pelvis-and-ureter-b044-c65c66/rulebase-malignant-neoplasm-renal-pelvis-and-ureter/cigarette-smoking
Injection with thorotrast
Current RMA Instruments
| Reasonable Hypothesis SOP | 92 of 2019 |
| Balance of Probabilities SOP | 93 of 2019 |
Changes from previous Instruments
ICD Coding
ICD-10-AM Codes: C65, C66
Brief description
This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder).
Confirming the diagnosis
The diagnosis requires confirmation by histology.
The relevant medical specialist is a urologist.
Additional diagnoses covered by SOP
- Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
Related conditions that may be covered by SOP (further information required)
- Cancer of the renal pelvis, renal calyx or ureter
- Renal pelvic and ureteric cancer
Conditions not covered by SOP
- Hodgkin’s lymphoma of the renal calyx, pelvis or ureter*
- Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)
- Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*
- Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)
- Soft-tissue sarcoma of the renal calyx, pelvis or ureter*
* another SOP applies
Clinical onset
The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.
Clinical worsening
The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-renal-pelvis-and-ureter-b044-c65c66/rulebase-malignant-neoplasm-renal-pelvis-and-ureter/injection-thorotrast
No appropriate clinical management for neoplasm of renal pelvis and ureter
Current RMA Instruments
| Reasonable Hypothesis SOP | 92 of 2019 |
| Balance of Probabilities SOP | 93 of 2019 |
Changes from previous Instruments
ICD Coding
ICD-10-AM Codes: C65, C66
Brief description
This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder).
Confirming the diagnosis
The diagnosis requires confirmation by histology.
The relevant medical specialist is a urologist.
Additional diagnoses covered by SOP
- Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
Related conditions that may be covered by SOP (further information required)
- Cancer of the renal pelvis, renal calyx or ureter
- Renal pelvic and ureteric cancer
Conditions not covered by SOP
- Hodgkin’s lymphoma of the renal calyx, pelvis or ureter*
- Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)
- Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*
- Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)
- Soft-tissue sarcoma of the renal calyx, pelvis or ureter*
* another SOP applies
Clinical onset
The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.
Clinical worsening
The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-renal-pelvis-and-ureter-b044-c65c66/rulebase-malignant-neoplasm-renal-pelvis-and-ureter/no-appropriate-clinical-management-neoplasm-renal-pelvis-and-ureter
Phenacetin consumption
Current RMA Instruments
| Reasonable Hypothesis SOP | 92 of 2019 |
| Balance of Probabilities SOP | 93 of 2019 |
Changes from previous Instruments
ICD Coding
ICD-10-AM Codes: C65, C66
Brief description
This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder).
Confirming the diagnosis
The diagnosis requires confirmation by histology.
The relevant medical specialist is a urologist.
Additional diagnoses covered by SOP
- Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
Related conditions that may be covered by SOP (further information required)
- Cancer of the renal pelvis, renal calyx or ureter
- Renal pelvic and ureteric cancer
Conditions not covered by SOP
- Hodgkin’s lymphoma of the renal calyx, pelvis or ureter*
- Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)
- Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*
- Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)
- Soft-tissue sarcoma of the renal calyx, pelvis or ureter*
* another SOP applies
Clinical onset
The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.
Clinical worsening
The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-renal-pelvis-and-ureter-b044-c65c66/rulebase-malignant-neoplasm-renal-pelvis-and-ureter/phenacetin-consumption
Pipe smoking
Current RMA Instruments
| Reasonable Hypothesis SOP | 92 of 2019 |
| Balance of Probabilities SOP | 93 of 2019 |
Changes from previous Instruments
ICD Coding
ICD-10-AM Codes: C65, C66
Brief description
This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder).
Confirming the diagnosis
The diagnosis requires confirmation by histology.
The relevant medical specialist is a urologist.
Additional diagnoses covered by SOP
- Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
Related conditions that may be covered by SOP (further information required)
- Cancer of the renal pelvis, renal calyx or ureter
- Renal pelvic and ureteric cancer
Conditions not covered by SOP
- Hodgkin’s lymphoma of the renal calyx, pelvis or ureter*
- Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)
- Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*
- Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)
- Soft-tissue sarcoma of the renal calyx, pelvis or ureter*
* another SOP applies
Clinical onset
The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.
Clinical worsening
The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-renal-pelvis-and-ureter-b044-c65c66/rulebase-malignant-neoplasm-renal-pelvis-and-ureter/pipe-smoking
Smoking tobacco products - material contribution
Current RMA Instruments
| Reasonable Hypothesis SOP | 92 of 2019 |
| Balance of Probabilities SOP | 93 of 2019 |
Changes from previous Instruments
ICD Coding
ICD-10-AM Codes: C65, C66
Brief description
This is a primary cancer of the renal pelvis (the structure that collects urine from the kidney and funnels it into the ureter), or the ureter (the tube that connects the kidney to the bladder).
Confirming the diagnosis
The diagnosis requires confirmation by histology.
The relevant medical specialist is a urologist.
Additional diagnoses covered by SOP
- Adenocarcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Neuroendocrine carcinoma (including malignant carcinoid) of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Squamous cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma in situ of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
- Transitional cell carcinoma of the renal calyx, renal pelvis, pelviureteric junction or ureter
Related conditions that may be covered by SOP (further information required)
- Cancer of the renal pelvis, renal calyx or ureter
- Renal pelvic and ureteric cancer
Conditions not covered by SOP
- Hodgkin’s lymphoma of the renal calyx, pelvis or ureter*
- Malignant neoplasm of ureteric orifice of bladder* (malignant neoplasm of the bladder SOP)
- Non-Hodgkin lymphoma of the renal calyx, pelvis or ureter*
- Secondary/metastatic cancer involving the renal calyx, pelvis or ureter (code to primary site)
- Soft-tissue sarcoma of the renal calyx, pelvis or ureter*
* another SOP applies
Clinical onset
The most common presentation is with haematuria (blood in the urine). Flank pain may also occur. Clinical onset will often be based on the first relevant symptoms. The condition may also be found incidentally, e.g., following radiological imaging or cystoscopy with ureteropyeloscopy for investigation of a bladder condition.
Clinical worsening
The only SOP worsening factor is for inability to obtain appropriate clinical management. The condition has a variable course and prognosis. It is amenable to treatment if found early. A delay in appropriate treatment could result in worsening of the condition. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-renal-pelvis-and-ureter-b044-c65c66/rulebase-malignant-neoplasm-renal-pelvis-and-ureter/smoking-tobacco-products-material-contribution